Existing HT CBB Kit Enables High-Throughput
Extraction of HMW DNA Tailored for HiFi With an Updated Workflow
for Animal Blood and Bacteria
MENLO
PARK, Calif., Jan. 15,
2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, today announced PanDNA, a versatile Nanobind DNA
extraction kit. This new offering expands the array of sample types
suitable for long-read sequencing, including cells, bacteria,
blood, tissue, plant nuclei, and insects.
Nanobind kits are designed for researchers to efficiently
extract high-quality, high molecular weight DNA across a wide range
of sample types. These kits are versatile, accommodating both
manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT
kit) settings. Their simple, rapid protocol is compatible with
platforms from PacBio's Compatible automation providers.
In addition, based on customer feedback, the existing
high-throughput extraction Nanobind HT CBB kit will now support two
new sample types – animal blood and bacteria – and can accommodate
96 samples per run.
"The new PanDNA kit will be the go-to kit for extracting DNA
optimized for HiFi sequencing," said Jeff
Eidel, Chief Commercial Officer at PacBio. "We continue to
enable our customers with products such as the PanDNA kit that
support researchers to complete accurate genome assemblies,
identify structural variants, and explore complex biological
systems in extraordinary detail using our Revio sequencing
system."
"Nanobind high molecular weight DNA extraction is a game-changer
for us and having one universal kit for all supported samples is
very convenient," said Igor
Stevanovski, Research Assistant at the Genomic Technologies
Lab, Garvan Institute of Medical Research – one of Australia's premier medical research
institutes. "The flexibility offered by the PanDNA kit will support
our broad research community to answer those key questions and make
important biological discoveries."
"The Darwin Tree of Life project aims to generate high quality
genomes for 70,000 species of plants, fungi, animals and protists
across Britain and Ireland. High-throughput solutions such as the
Nanobind CBB HT kit are critical for efforts like these," said
Caroline Howard, Senior Scientific
Manager, Tree of Life Programme at the Wellcome Sanger Institute.
"The Nanobind kits combined with the Revio system address these
needs by significantly increasing throughput. Using the kits, we
were able to generate 30x coverage of HiFi data sufficient for de
novo assembly."
The new PanDNA kit is expected to be available for purchase and
shipment in February 2024. The
Nanobind HT CBB kit is available now. For more information, visit
the Nanobind extraction kit page here.
About PacBio
PacBio (NASDAQ: PACB) is a premier life
science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technologies stem from two highly differentiated core
technologies focused on accuracy, quality and completeness which
include our HiFi long-read sequencing and our SBB® short-read
sequencing technologies. Our products address solutions across a
broad set of research applications including human germline
sequencing, plant and animal sciences, infectious disease and
microbiology, oncology, and other emerging applications. For more
information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release may
contain "forward-looking statements" within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, and the
U.S. Private Securities Litigation Reform Act of 1995. All
statements other than statements of historical fact are
forward-looking statements, including statements relating to future
availability, uses, advantages, quality or performance of, or
benefits or expected benefits of using, PacBio products or
technologies, including Nanobind PanDNA kits; statements regarding
DNA extraction across a wide range of sample types; PanDNA kits as
a go-to kit for HiFi sequencing and its ability to support a broad
research community; among other future events. Readers are
cautioned not to place undue reliance on these forward-looking
statements and any such forward-looking statements are qualified in
their entirety by reference to the following cautionary statements.
All forward-looking statements speak only as of the date of this
press release and are based on current expectations and involve a
number of assumptions, risks and uncertainties that could cause the
actual results to differ materially from such forward-looking
statements. These risks include, but are not limited to, challenges
inherent in developing, manufacturing, launching, marketing and
selling new products; potential product performance and quality
issues and potential delays in development and commercialization
timelines; rapidly changing technologies and extensive competition
in genomic sequencing that could make the products PacBio is
developing obsolete or non-competitive; and third-party claims
alleging infringement of patents and proprietary rights or seeking
to invalidate PacBio's patents or proprietary rights. Readers are
strongly encouraged to read the full cautionary statements
contained in PacBio's filings with the Securities and Exchange
Commission, including the risks set forth in PacBio's Forms 8-K,
10-K, and 10-Q. PacBio disclaims any obligation to update or revise
any forward-looking statements.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-new-nanobind-pandna-kit-enabling-hifi-optimized-dna-extraction-solutions-302034274.html
SOURCE Pacific Biosciences of California, Inc.